Elanco Animal Health Inc. has announced that its product, Credelio Quattro, has achieved blockbuster status with $100 million in net sales, marking it as the fastest pet health blockbuster in the company's history and among the industry's fastest with a single geographic approval. This milestone underscores the strong demand for all-in-one parasite protection products from veterinarians and pet owners. Credelio Quattro, known for providing broad parasite protection against fleas, ticks, heartworm disease, and three intestinal parasites, has captured approximately 14% of the dollar share in broad-spectrum sales out of U.S. veterinary clinics. This achievement has reinforced Elanco's position in the U.S. veterinary market, enhancing their portfolio with a comprehensive range of parasite coverage options. Additionally, Elanco's recently launched product Zenrelia is now available in the European Union and Great Britain, following a successful head-to-head non-inferiority study against the marketplace incumbent, Apoquel, published in the journal Veterinary Dermatology. There were no specific updates provided regarding sales/revenues, net income/profit/loss, or earnings per share for other products or the company as a whole.